Dubai – United Arab Emirates: Under the patronage of His Highness Sheikh Hamdan bin Rashid Al Maktoum, Deputy Ruler of Dubai, Minister of Finance and President of Dubai Health Authority, the Dubai International Pharmaceutical and Technology Conference and Exhibition – DUPHAT, the leading pharma event in the Middle East and North Africa region, dedicated to pharmacists, drug manufacturers and distributors will be held from the 26th to the 28th of February, 2019 at the Dubai International Convention and Exhibition Centre.
The 24th edition of DUPHAT comes at a time when the pharmaceutical market in the GCC and more specifically in the UAE is rapidly growing and becoming a regional drug manufacturing hub. As more and more international pharmaceutical companies consider setting up drug manufacturing bases in the UAE and the UAE’s appetite for high quality generic medications is continuously rising, the outlook for the pharmaceutical industry in the country looks promising for future investment.
This year, DUPHAT is expected to attract over 27,500 visitors and participants from 75 countries, witness the attendance of 130 speakers; 143 scientific lectures, 700 poster presentations and 22 workshops designed for the benefit of everyone attending the premier pharma event. The 3-day program will also feature discussions on a number of topics including pharmacy practice, pharmaceutical science, quality and safety of medicines, medication management, drug recalls and shortages and skills training and education. Additionally, DUPHAT exhibition, which is occupying an overall space of 21,000 square meters, is set to feature the presence of 659 leading drug manufacturing and technology brands from the global pharmaceutical industry while also having the presence of 2 country pavilions representing India and China.
Speaking on the occasion, Dr. Ali Al Sayed Hussain, Scientific Chairman, DUPHAT, said, “The pharmaceutical industry in the UAE is witnessing a rapid growth every year owing to a number of factors such as rapid advances in medical treatments and technologies, new innovative devices and drugs for chronic diseases and a consistent rise in healthcare spending. In addition, the rising healthcare costs are also driving innovation in the modern pharma market, where increasingly more and more pharma companies are willing to customize their offerings and develop innovative products, services and solutions. We are confident that these positive trends will continue to drive the growth of the pharmaceutical sector in the UAE and attract leading pharmaceutical companies to set up drug manufacturing bases in the country.”
He added, “This year, DUPHAT features a very exciting scientific program, with a key focus on a number of topics affecting the pharmaceutical and drug manufacturing industry in the region such as ‘The Pharmacist in Focus, Bridging Pharmacy Education and Practice, Pharmacy Practice Perspectives, Policy and Approach in Medication Management, Future Perspectives in Pharmacy, Expanding the Role of Pharmacist and Pharmacy Service, Strategies and Governance in Pharmacy among others. Moreover, the conference comprises various pharmacy workshops, managerial skills workshops, scientific presentations, professional faculty and student poster presentation, student poster competition and student short oral presentation competitions. We hope that DUPHAT will offer all attendees a great opportunity to learn about latest trends in the industry while also give them a chance to dialogue with leading professionals, researchers and academic experts in pharmacy.”
For the first time, DUPHAT is featuring the launch of a parallel conference on ‘Pharmacy Regulatory and Manufacturing’, bringing together top industry experts, pharmacists and industry professionals from the UAE and abroad. The conference will highlight a number of issues related to latest advancements in drug manufacturing, new technologies, digitization and more importantly the regulatory mechanisms and legislations necessary for the approval of biological medicines. In addition, a workshop on the sidelines will focus on ‘Pharmacists Contribution to Change in the Year of Tolerance’, where experts will discuss the role of pharmacists in providing patient centered services while also giving them a chance to learn about patient’s expectations and demands.
Running parallel to the DUPHAT Conference, DUPHAT-Tech this year features the leading exhibition, offering leading pharmaceutical companies a chance to showcase their latest products and technologies covering the entire manufacturing chain of the pharmaceutical industry from essential drug ingredients to finished products, as well as formulating, processing, filling, packaging and labelling of products.
Furthermore, DUPHAT conference attendees will get a chance to receive 36.25 CME points accredited by DHA and 22 points from The Society of Hospital Pharmacists of Australia (SHPA) while also having an opportunity to interact with the top pharmaceutical experts, executives and CEO’s and learn about the future trends in the industry.
DUPHAT is organized annually by INDEX Conferences and Exhibitions – a member of INDEX Holding in strategic partnership with General Directorate of Residency and Foreigners Affairs (GDRFA) Dubai and is supported by Dubai Health Authority, International Society for Pharmacoepidemiology, European Society of Oncology Pharmacy, European Federation for Pharmaceutical science, European society of Clinical pharmacy.
-Ends-
© Press Release 2019Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
